NCT03622216

A Dose Escalation Study of Bradanicline in Refractory Chronic Cough

A Dose Escalation Study to Assess the Efficacy and Safety of Bradanicline in Subjects With Refractory Chronic Cough

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Attenua, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled, crossover, dose escalation study of bradanicline in subjects with chronic cough

Detailed description

This study will have two 21-day treatment periods separated by a 14-day washout period. There will be a 14-day follow-up period.

Conditions

• Chronic Cough

Interventions

Type	Name	Description
DRUG	Bradanicline	Three different doses over the course of the study
DRUG	Placebo	Matching placebo for Bradanicline

Timeline

• Start date: 2018-11-05
• Primary completion: 2019-05-07
• Completion: 2019-05-22
• First posted: 2018-08-09
• Last updated: 2019-06-20

Locations

17 sites across 1 country: United States

Regulatory

• FDA-regulated drug study